Baker Brothers portfolio, Q2 2026
Baker Bros. Advisors · 13F for the quarter ending Jun 30, 2026
For Q2 2026, Baker Bros. Advisors reported $20B across 84 US-listed positions, led by INCY (17.5%), ONC (12.6%) and RVMD (10.7%). Compared with its filing for Q1 2026, Baker Brothers opened 8 new positions, added to 16, reduced 7 and sold out of 8; 52 positions did not change.
The largest purchase was an addition to RVMD ($353.6M); the largest sale, a reduction of EWTX ($116.8M).
This is the latest filing on file; the main portfolio page shows the same holdings against today's prices.
Key facts
- 13F portfolio value
- $20BQ2 2026
- Positions
- 84
- Largest holding
- INCY 17.5%
- New positions
- 8
- Sold out
- 8
- Filed
- Aug 14, 2026
Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Every tracked investor's Q2 2026 13F.
Bought and sold in Q2 2026
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Revolution Medicines IncRVMD | ▲ Added 20% | +1.89M | $353.6M | 1.77% |
| Insmed IncINSM | ▲ Added 19% | +1.38M | $146.6M | 0.73% |
| Edgewise Therapeutics IncEWTX | ▼ Reduced 44% | −2.87M | $116.8M | 0.59% |
| Abivax SAABVX | ▼ Sold out | −875.8K | $97.5M | 0.49% |
| Summit Therapeutics IncSMMT | ▼ Reduced 9.9% | −3.6M | $52.5M | 0.26% |
| Spyre Therapeutics IncSYRE | ▼ Sold out | −1M | $50.4M | 0.25% |
| IDEAYA Biosciences IncIDYA | ▲ Added 27% | +1.06M | $39.6M | 0.20% |
| Faeth Therapeutics IncFTH | ▲ New | +1.29M | $32.2M | 0.16% |
| Relay Therapeutics IncRLAY | ▲ Added 144% | +1.67M | $31.2M | 0.16% |
Centessa Pharmaceuticals PLCno ticker on file | ▼ Sold out | −670.75K | $26.6M | 0.13% |
| Immunocore Holdings plcIMCR | ▼ Sold out | −734.4K | $22.1M | 0.11% |
| Abcellera Biologics IncABCL | ▲ Added 9.0% | +2.74M | $21.5M | 0.11% |
| Celldex Therapeutics IncCLDX | ▲ Added 78% | +517.24K | $19.2M | 0.10% |
| Contineum Therapeutics IncCTNM | ▼ Sold out | −1.42M | $18.6M | 0.09% |
| argenx SEARGX | ▼ Sold out | −25.17K | $18.4M | 0.09% |
| Cytokinetics IncCYTK | ▲ New | +211.27K | $18M | 0.09% |
| Intellia Therapeutics IncNTLA | ▲ New | +930.23K | $15.7M | 0.08% |
| Immatics N.V.IMTX | ▼ Reduced 13% | −1.41M | $14.3M | 0.07% |
| Parabilis Medicines IncPBLS | ▲ New | +500K | $13.7M | 0.07% |
| Arcus Biosciences IncRCUS | ▲ Added 103% | +429.2K | $13.2M | 0.07% |
| Compass Pathways PlcCMPS | ▼ Sold out | −2.34M | $13M | 0.06% |
| Avalyn Pharma IncAVLN | ▲ New | +350K | $11.5M | 0.06% |
| Pharvaris N VPHVS | ▼ Sold out | −375K | $10.6M | 0.05% |
| Cerus CorpCERS | ▼ Reduced 36% | −3.61M | $10.5M | 0.05% |
| Tango Therapeutics IncTNGX | ▲ New | +333.33K | $10.4M | 0.05% |
| Avalo Therapeutics IncAVTX | ▲ New | +550K | $10.2M | 0.05% |
| Jade Biosciences IncJBIO | ▼ Reduced 25% | −410.71K | $9.1M | 0.05% |
| Viridian Therapeutics IncVRDN | ▲ Added 21% | +411.35K | $7.6M | 0.04% |
| Verastem IncVSTM | ▲ Added 327% | +1.91M | $7.3M | 0.04% |
| Roivant Sciences LtdROIV | ▼ Reduced 3.1% | −150.89K | $5.3M | 0.03% |
| Incyte CorpINCY | ▲ Added 0.06% | +17.92K | $2M | 0.01% |
| Design Therapeutics IncDSGN | ▲ Added 3.6% | +92.45K | $1.3M | 0.01% |
| Immunome IncIMNM | ▲ New | +55.31K | $1.2M | 0.01% |
| Immunovant IncIMVT | ▼ Reduced 0.4% | −22.66K | $873.1K | 0.00% |
| Madrigal Pharmaceuticals IncMDGL | ▲ Added 0.07% | +1.43K | $767.8K | 0.00% |
| Beone Medicines LtdONC | ▲ Added 0.03% | +2.51K | $716.4K | 0.00% |
| Kiniksa Pharmaceuticals InternationalKNSA | ▲ Added 0.3% | +8.4K | $537K | 0.00% |
| Acadia Pharmaceuticals IncACAD | ▲ Added 0.04% | +16.21K | $410.2K | 0.00% |
| Denali Therapeutics IncDNLI | ▲ Added 0.07% | +2.64K | $67.9K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q1 2026 |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte CorpINCY | Health Care | 17.5% | $3.5B | 30.76M | $113.36 | 9+ qtrs | ▲ Added 0.06% |
| 2 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 12.6% | $2.5B | 8.8M | $284.97 | 9+ qtrs | ▲ Added 0.03% |
| 3 | Revolution Medicines IncRVMD | Health Care | 10.7% | $2.1B | 11.44M | $187.28 | 9+ qtrs | ▲ Added 20% |
| 4 | Madrigal Pharmaceuticals IncMDGL | Health Care | 5.77% | $1.2B | 2.14M | $536.95 | 9+ qtrs | ▲ Added 0.07% |
| 5 | Acadia Pharmaceuticals IncACAD | — | 5.44% | $1.1B | 42.91M | $25.30 | 9+ qtrs | ▲ Added 0.04% |
| 6 | Kymera Therapeutics IncKYMR | Health Care | 4.98% | $992.7M | 8.66M | $114.67 | 9+ qtrs | No change |
| 7 | Insmed IncINSM | Health Care | 4.70% | $937.8M | 8.8M | $106.62 | 9+ qtrs | ▲ Added 19% |
| 8 | Celcuity IncCELC | — | 4.15% | $828.2M | 7.92M | $104.62 | 9+ qtrs | No change |
| 9 | Kodiak Sciences IncKOD | Health Care | 3.89% | $776.1M | 19.92M | $38.96 | 9+ qtrs | No change |
| 10 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.12% | $622.3M | 5.6M | $111.03 | 9+ qtrs | No change |
| 11 | Praxis Precision MedicinesPRAX | Health Care | 2.94% | $587M | 1.75M | $334.79 | 9+ qtrs | No change |
| 12 | Alkermes PLCALKS · SHS | Health Care | 2.63% | $524.6M | 10.01M | $52.39 | 9+ qtrs | No change |
| 13 | Summit Therapeutics IncSMMT | Health Care | 2.39% | $477.7M | 32.79M | $14.57 | 9+ qtrs | ▼ Reduced 9.9% |
| 14 | Grail IncGRAL | Health Care | 1.38% | $275M | 4.03M | $68.27 | 7 qtrs | No change |
| 15 | Abcellera Biologics IncABCL | — | 1.30% | $259.1M | 33.01M | $7.85 | 9+ qtrs | ▲ Added 9.0% |
| 16 | Immunovant IncIMVT | Health Care | 1.05% | $209.4M | 5.44M | $38.53 | 9+ qtrs | ▼ Reduced 0.4% |
| 17 | IDEAYA Biosciences IncIDYA | — | 0.94% | $186.7M | 5.01M | $37.27 | 9+ qtrs | ▲ Added 27% |
| 18 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.91% | $181.3M | 2.83M | $63.95 | 9+ qtrs | ▲ Added 0.3% |
| 19 | Roivant Sciences LtdROIV · SHS | Health Care | 0.84% | $166.9M | 4.72M | $35.39 | 9+ qtrs | ▼ Reduced 3.1% |
| 20 | Arrowhead PharmaceuticalsARWR | Health Care | 0.81% | $162.4M | 1.99M | $81.51 | 5 qtrs | No change |
| 21 | Ionis Pharmaceuticals IncIONS | Health Care | 0.81% | $162.4M | 2.05M | $79.29 | 4 qtrs | No change |
| 22 | Edgewise Therapeutics IncEWTX | Health Care | 0.75% | $150.4M | 3.7M | $40.63 | 9+ qtrs | ▼ Reduced 44% |
| 23 | Replimune Group IncREPL | — | 0.61% | $122.3M | 11.05M | $11.07 | 9+ qtrs | No change |
| 24 | Nurix Therapeutics IncNRIX | — | 0.57% | $113M | 4.66M | $24.26 | 9+ qtrs | No change |
| 25 | Stoke Therapeutics IncSTOK | — | 0.55% | $109.2M | 3.34M | $32.72 | 9+ qtrs | No change |
| 26 | Monte Rosa Therapeutics IncGLUE | — | 0.53% | $105.2M | 4.35M | $24.20 | 9+ qtrs | No change |
| 27 | Immatics N.V.IMTX · SHS | — | 0.48% | $96.3M | 9.51M | $10.13 | 9+ qtrs | ▼ Reduced 13% |
| 28 | Denali Therapeutics IncDNLI | — | 0.48% | $96M | 3.73M | $25.72 | 9+ qtrs | ▲ Added 0.07% |
| 29 | Crinetics Pharmaceuticalsno ticker on file | — | 0.44% | $88M | 2.35M | $37.42 | 5 qtrs | No change |
| 30 | Dianthus Therapeutics IncDNTH | Health Care | 0.42% | $83.1M | 852.16K | $97.48 | 5 qtrs | No change |
| 31 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.39% | $76.9M | 1.43M | $53.67 | 8 qtrs | No change |
| 32 | Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031 | — | 0.35% | $69.2M | — | — | 4 qtrs | — |
| 33 | Rapport Therapeutics IncRAPP | — | 0.32% | $64.5M | 1.55M | $41.67 | 5 qtrs | No change |
| 34 | Alumis IncALMS | — | 0.28% | $56.6M | 2.01M | $28.14 | 9+ qtrs | No change |
| 35 | Prelude Therapeutics IncPRLD | — | 0.27% | $54M | 10.12M | $5.33 | 9+ qtrs | No change |
| 36 | Relay Therapeutics IncRLAY | — | 0.27% | $52.9M | 2.83M | $18.71 | 9+ qtrs | ▲ Added 144% |
| 37 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.26% | $52.2M | 445.98K | $117.07 | 2 qtrs | No change |
| 38 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 0.23% | $46.2M | 10.89M | $4.24 | 9+ qtrs | No change |
| 39 | Enliven Therapeutics IncELVN | — | 0.23% | $45.9M | 905.19K | $50.75 | 9+ qtrs | No change |
| 40 | Celldex Therapeutics IncCLDX | — | 0.22% | $44M | 1.18M | $37.21 | 9+ qtrs | ▲ Added 78% |
| 41 | Viridian Therapeutics IncVRDN | — | 0.22% | $43.8M | 2.38M | $18.37 | 5 qtrs | ▲ Added 21% |
| 42 | Design Therapeutics IncDSGN | — | 0.19% | $38.8M | 2.68M | $14.47 | 9+ qtrs | ▲ Added 3.6% |
| 43 | Entrada Therapeutics IncTRDA | — | 0.19% | $37.3M | 5.07M | $7.36 | 9+ qtrs | No change |
| 44 | Faeth Therapeutics IncFTH | — | 0.16% | $32.2M | 1.29M | $25.00 | 1 qtr | New |
| 45 | Aktis Oncology IncAKTS | — | 0.16% | $32.1M | 996.35K | $32.23 | 2 qtrs | No change |
| 46 | Neurogene IncNGNE | — | 0.16% | $31.2M | 991.69K | $31.45 | 9+ qtrs | No change |
| 47 | Jade Biosciences IncJBIO | — | 0.14% | $27.3M | 1.23M | $22.22 | 3 qtrs | ▼ Reduced 25% |
| 48 | Taysha Gene Therapies IncTSHA | — | 0.14% | $27.3M | 4M | $6.81 | 9+ qtrs | No change |
| 49 | Arcus Biosciences IncRCUS | — | 0.13% | $26M | 844.82K | $30.83 | 3 qtrs | ▲ Added 103% |
| 50 | Disc Medicine IncIRON | — | 0.13% | $25.6M | 349.66K | $73.14 | 7 qtrs | No change |
| 51 | Absci CorpABSI | — | 0.12% | $24.7M | 2.13M | $11.59 | 3 qtrs | No change |
| 52 | Generate Biomedicines IncGENB | — | 0.12% | $24M | 1.42M | $16.87 | 2 qtrs | No change |
| 53 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.12% | $24M | 1.46M | $16.40 | 9+ qtrs | No change |
| 54 | Xenon Pharmaceuticals IncXENE | — | 0.11% | $22.3M | 370.21K | $60.36 | 9+ qtrs | No change |
| 55 | Tectonic Therapeutic IncTECX | — | 0.11% | $20.9M | 607.79K | $34.38 | 6 qtrs | No change |
| 56 | Cerus CorpCERS | — | 0.09% | $18.7M | 6.4M | $2.92 | 9+ qtrs | ▼ Reduced 36% |
| 57 | CytomX Therapeutics IncCTMX | — | 0.09% | $18.7M | 4.98M | $3.75 | 5 qtrs | No change |
| 58 | Dyne Therapeutics IncDYN | — | 0.09% | $18.1M | 813.45K | $22.21 | 3 qtrs | No change |
| 59 | Cytokinetics IncCYTK | Health Care | 0.09% | $18M | 211.27K | $85.19 | 1 qtr | New |
| 60 | Xencor IncXNCR | — | 0.09% | $17.7M | 1.1M | $16.10 | 9+ qtrs | No change |
| 61 | Sionna Therapeutics IncSION | — | 0.09% | $17.6M | 400K | $43.99 | 6 qtrs | No change |
| 62 | Intellia Therapeutics IncNTLA | — | 0.08% | $15.7M | 930.23K | $16.92 | 1 qtr | New |
| 63 | Parabilis Medicines IncPBLS | — | 0.07% | $13.7M | 500K | $27.37 | 1 qtr | New |
| 64 | Maplight Therapeutics IncMPLT | — | 0.07% | $13.1M | 364.71K | $35.84 | 3 qtrs | No change |
| 65 | Avalyn Pharma IncAVLN | — | 0.06% | $11.5M | 350K | $32.92 | 1 qtr | New |
| 66 | Evommune IncEVMN | — | 0.06% | $11.3M | 847.39K | $13.29 | 2 qtrs | No change |
| 67 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.06% | $11.1M | 119.74K | $93.05 | 7 qtrs | No change |
| 68 | Tango Therapeutics IncTNGX | — | 0.05% | $10.4M | 333.33K | $31.26 | 1 qtr | New |
| 69 | Avalo Therapeutics IncAVTX | — | 0.05% | $10.2M | 550K | $18.48 | 1 qtr | New |
| 70 | Sera Prognostics IncSERA · CLASS A COM | — | 0.05% | $10M | 5.5M | $1.82 | 9+ qtrs | No change |
| 71 | Verastem IncVSTM | — | 0.05% | $9.5M | 2.5M | $3.82 | 2 qtrs | ▲ Added 327% |
| 72 | Sagimet Biosciences IncSGMT | — | 0.04% | $7.4M | 953K | $7.73 | 9+ qtrs | No change |
| 73 | Eikon Therapeutics IncEIKN | — | 0.04% | $7.2M | 555.56K | $13.05 | 2 qtrs | No change |
| 74 | LB Pharmaceuticals IncLBRX | — | 0.03% | $6.5M | 200K | $32.46 | 4 qtrs | No change |
| 75 | vTv Therapeutics IncVTVT · CL A | — | 0.03% | $5.6M | 148.31K | $37.65 | 9+ qtrs | No change |
| 76 | Wave Life Sciences LtdWVE · SHS | — | 0.02% | $4.8M | 822.64K | $5.81 | 8 qtrs | No change |
| 77 | Protara Therapeutics IncTARA | — | 0.02% | $3.7M | 971.61K | $3.82 | 9+ qtrs | No change |
| 78 | TScan Therapeutics IncTCRX | — | 0.01% | $2.7M | 2.78M | $0.9801 | 9+ qtrs | No change |
| 79 | Immunome IncIMNM | — | 0.01% | $1.2M | 55.31K | $21.19 | 1 qtr | New |
| 80 | Skye Bioscience IncSKYE | — | 0.01% | $1.1M | 1.58M | $0.6933 | 9+ qtrs | No change |
| 81 | Sana Biotechnology IncSANA | — | 0.01% | $1.1M | 310.48K | $3.49 | 9+ qtrs | No change |
| 82 | Aligos Therapeutics IncALGS | — | 0.00% | $479.2K | 83.06K | $5.77 | 9+ qtrs | No change |
| 83 | Tyra Biosciences IncTYRA | — | 0.00% | $338.8K | 10.61K | $31.94 | 9+ qtrs | No change |
| 84 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $13.8K | 833.33K | $0.0165 | 9+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 78.6% | $15.7B | 22 |
| No sector on file | 21.4% | $4.3B | 62 |
Questions and answers
What did Baker Brothers own in Q2 2026?
Baker Bros. Advisors's 13F for Q2 2026 lists 84 positions worth $20B. The largest: INCY (17.5%), ONC (12.6%), RVMD (10.7%), MDGL (5.8%), ACAD (5.4%).
What did Baker Brothers buy in Q2 2026?
The largest purchases, by the shares bought at the quarter-end price the filing implies: RVMD (added, $353.6M), INSM (added, $146.6M), IDYA (added, $39.6M), FTH (new, $32.2M), RLAY (added, $31.2M), ABCL (added, $21.5M).
What did Baker Brothers sell in Q2 2026?
The largest sales: EWTX (reduced, $116.8M), ABVX (sold out, $97.5M), SMMT (reduced, $52.5M), SYRE (sold out, $50.4M), Centessa Pharmaceuticals PLC (sold out, $26.6M), IMCR (sold out, $22.1M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Jun 30, 2026 on Aug 14, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q2 2026: Baker Bros. Advisors 13F holdings”, data as of 14 August 2026. https://funkfolio.com/gurus/baker-brothers/2026-q2
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Jun 30, 2026.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Jun 30, 2026, filed Aug 14, 2026. Changes compare share counts with the filing for Mar 31, 2026; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $20B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 9 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.